Virax Biolabs Group Ltd cash flow statement

In fiscal 2026, Virax Biolabs Group Ltd's operations generated −$4.6m of cash; it spent $255,831 on capital projects, leaving free cash flow of −$4.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Virax Biolabs Group Ltd: cash flow statement, annual
Fiscal year	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Cash from operations	−590	−809	−4,180	−6,397	−4,564	−4,622
Depreciation and amortisation	—	0	0	55	267	361
Stock-based pay	—	290	1,735	1,012	365	130
Capital spending	—	—	—	952	604	256
Free cash flow	—	—	—	−7,349	−5,167	−4,878
Free cash flow after stock pay	—	—	—	−8,361	−5,533	−5,008

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: LYEL vs VRAX CELZ vs VRAX AIM vs VRAX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Virax Biolabs Group Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Virax Biolabs Group Ltd.